JPMorgan lowered the firm’s price target on Caris Life Sciences (CAI) to $30 from $35 and keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences price target lowered to $28 from $35 at Citi
- Analyst Reiterates Buy as Strong Revenue, Improving Profitability Offset Near-Term Risks; Price Target Trimmed to $31
- Caris Life Sciences Earnings Call Signals Profitable Surge
- Caris Life Sciences reports Q1 EPS 0c, consensus (2c)
- Caris Life Sciences still sees 2026 revenue $1.0B-$1.02B, consensus $1.01B